

Pharmaceutical Nanosciences and their Application in the Delivery of Various Phytoconstituents

by Andang Miatmoko

Submission date: 30-Mar-2023 01:02PM (UTC+0800)

Submission ID: 2050706847

File name: eir_Application_in_the_Delivery_of_Various_Phytoconstituents.pdf (8.29M)

Word count: 11872

Character count: 75592

CHAPTER 1

Pharmaceutical Nanosciences and their Application in the Delivery of Various Phytoconstituents

Retno Widyowati^{1,2,*} and Andang Miatmoko¹

¹ Department of Pharmaceutical Science, Faculty of Pharmacy, Universitas Airlangga, Surabaya, 60115, Indonesia

² Natural Product Drug Discovery and Development Research Group, Faculty of Pharmacy, Universitas Airlangga, Surabaya, 60115, Indonesia

Abstract: Nanoscience provides numerous opportunities for pharmaceutical scientists. Due to the continuing progress of nanoparticle-based medicines, the opportunity to treat and combat difficult diseases, especially with herbal remedies, can be achieved. The use of herbs is effective when their active constituents reach the intended target. However, the flavonoids, tannins, and terpenoids present in herbs are hydrophilic and unable to pass through cell lipid membranes. Therefore, their absorption is poor, resulting in reduced availability and biological efficacy, increased dosage, and frequency of use. Nanoengineering has verified that nanoparticles have significant potential as drug carriers. Size reduction methods and technologies produce a wide variety of nanostructures, which are indicative of specific physicochemical and biological properties. This delivery system plays an essential role in increasing the solubility, bioavailability, pharmacological effect, stability, effectiveness, selectivity, and drug specificity of its bioactive constituents. Nanoscale models such as phytosomes, liposomes, nanoemulsions, nanoparticles, solid lipid nanoparticles, and ethosomes are used to deliver various bioactive constituents at adequate doses to the target during the entire treatment period. Phospholipid complex techniques have recently been introduced to overcome these barriers either by enhancing their dissolving capacity or their potential ability to traverse biological membranes and protect the active herbal constituents against degradation. Therefore, this chapter discusses the application of nanoscience for delivering various phytoconstituents in order to achieve therapeutic targets.

Keywords: Herbal medicine, Nanotechnology, Phytoconstituents.

* Corresponding author Retno Widyowati: Department of Pharmaceutical Science, Faculty of Pharmacy, Universitas Airlangga, Surabaya, 60115, Indonesia; E-mail: rr-retno-w@ff.unair.ac.id and Natural Product Drug Discovery and Development Research Group, Faculty of Pharmacy, Universitas Airlangga, Surabaya, 60115, Indonesia

INTRODUCTION

Nanotechnology is a science that changes the dimensions of matter at the nanoscale level. Recently, this branch of science has been indispensable to the pharmaceutical and drug industries because of its potential to play a crucial role in improving human life. These scientific applications are related to the medical field and include the therapeutic applications of drug delivery, enhancing drug efficacy, reducing side effects, and improving circulation and stability [1]. The majority of phytoconstituents are declared active if they are proven to have a confirmed impact on the treatment of specific diseases or pain relief and are classified as organic constituents. The active organic constituents demonstrate low bioavailability while being predominantly non-water soluble, unstable, and the most toxic.

Nanoparticles are frequently used as therapeutic and diagnostic agents because of their advanced and essential drug delivery systems. For example, materials incorporating protein or nucleic acids require a carrier system that potentially enhances their effectiveness and shields them from undesired degradation [2]. The potency of the drug nanoparticle delivery system is directly associated with its small particles and huge surface area, thus indicating increased solubility and the capacity to pass through the blood-brain barrier (BBB), enter the respiratory system, and be captivated across the close connections of skin epithelial tissue cells [3].

Formulations based on herbal medicines or their active phytoconstituents remain subjected to numerous limitations [4]. Nevertheless, they are considered a major source because of their less severe side effects compared to those of synthetic drugs and the deep-seated public belief in their ability to cure or prevent various diseases. Several methods are employed to overcome these limitations, including dissolving in non-polar solvents, making injection preparations, and increasing their solubility by changing the active phytoconstituents into their salt form. These methods have several drawbacks, such as high solvent toxicity, their uncertain activity when in salt form, the presence of bioactive drug forms, and the lack of bioavailability. Consequently, special technology, namely nanotechnology, needs to be employed as a solution. With the application of nanotechnology, herbal medicines can deliver their active phytoconstituents to specific targets. These nanoparticle techniques are designed and delivered with various sizes, forms, compositions, functions, and physical/chemical modifications to suit the distinctiveness of the targeted organs and the specific drug used. The dosage forms of nanoparticles include fullerenes, emulsions, microemulsions, liposomes, liquid crystals, dendrimers, quantum dots, nanoparticles, gels, solid lipid nanoparticles, among others. This chapter will,

therefore, briefly focus on herbal medicine nanoparticles to overcome several formulation deficiencies associated with phytoconstituents in herbs.

PHYTOCONSTITUENTS IN HERBAL MEDICINE

Phytoconstituents found in herbs are commonly referred to as secondary metabolites, namely phenolics, terpenoids, alkaloids, and anthraquinones. These compounds have high curative value, but their bioavailability and solubility are low, while their toxicity and instability may hinder their medicinal use [5].

Phenolic

Almost all plants contain phenolic compounds which are aromatic in character and contain more than one hydroxyl substituent. The main compounds are phenols, many of which are found in polyphenols, and among which more than 8,000 compounds have been identified. Based on their primary chemical structures, polyphenols are divided into stilbenes, phenolic acids, flavonoids, and lignans. Flavonoids are one of the naturally occurring polyphenols, with more than 6,000 compounds being identified. They include flavones, flavonols, flavans, flavanones, dihydroflavanols, isoflavons, and biflavones [6]. Compounds within this class execute a protective function against free radicals, cardiovascular disease, cancer, inflammation, microbial contamination, viruses, allergies, and ulcers, among other diseases [7]. Other phenolic compounds include quinones, xanthenes, coumarins, polymer lignins, and tannins. Phenylpropanoid dimers or lignans containing two C6-C3 bound by C-8 carbon centres have antiviral, anticancer, anti-inflammatory, antimicrobial, antioxidant, immunosuppressive, and hepatoprotective properties and are used in osteoporosis prevention [8].

Polyphenols have properties that are challenging to address due to the presence of several phenyl rings in the compound, the number of hydroxyl groups in the aromatic cycle, and the bioavailability of polyphenols in food that depends on pre- and post-harvest conditions and interactions with other compounds. Since these class compounds demonstrate extremely limited absorption ability, poor solubility in water, and rapid metabolism, they need to be made into several types of pharmaceutical formulations with the potential to increase bioavailability. Certain polyphenols have low stability and, therefore, selecting the liposome form for polyphenol encapsulation is considered appropriate. However, it is also important to note the characteristics of each polyphenol, which have various molecular structures within which the ring and hydroxyl numbers affect their solubility [7]. One example is that of a podophyllotoxin employed as an anti-mitotic whose high toxicity limits its use [9]. To overcome this problem, modification of the podophyllotoxin structure is undertaken in the hope that its toxicity will be reduced.

Resveratrol is a polyphenol compound contained in *Vitis vinifera*, labrusca, and muscadine [10], which possesses anti-oxidant, anti-cancer, anti-inflammatory, and cardioprotective properties [11]. Due to being moderately water-soluble, resveratrol demonstrates full bioavailability, photosensitivity [12], and rapid metabolism [13]. Multiple nanoencapsulation of resveratrol, polymer nanoparticles, Zein-based nanoparticles, nanoemulsions, liposomes, cyclodextrins, and resveratrol have been reported to enhance bioavailability and pharmacokinetics [14 - 19]. The polyphenol will improve solubility and chemical stability if formulated with dipalmytoyl-phosphatidylcholine or distearoyl-phosphatidylethanolamine-polyethylene glycol 2000. It also prolongs efficacy and improves protection from UV B when combined with P90G or dicetyl phosphate [7].

Curcumin (diferuloyl-methane) is moderately soluble in water, has low bioavailability and is produced in the formulation of liposomes, phospholipid vesicles, and polymer-based nano formulations [20, 21]. Oral bioavailability is nine times higher when curcumin is combined with piperine, which functions as an absorption enhancer [22]. In addition, curcumin colloid nanoparticles (theracurmin) are 27 times more effective and can inhibit alcohol poisoning [23]. Curcumin formulated in liposomes using soybean phosphatidylcholine, film hydration, and extrusion (MLV) will prolong the antioxidant protective effect. On the other hand, when formulated using dimyristoyl phosphatidylglycerol and lyophilisate, it enhances the bioavailability while reducing the incidence of protease cancer and exerting an antiangiogenic effect [7].

Quercetin, a natural flavonoid in various vegetables and fruits, is 100 times more water-soluble after being formulated as a polymer nanoparticle suspension dosage form [24]. Ampelopsin, produced from *Ampelopsis grossedentata*, has anti-oxidant, anti-inflammatory, anti-hypertensive, anti-microbial, hepatoprotective, anti-carcinogenic properties, and cough-relieving effects. This compound is moderately water-soluble with very low permeability and is consequently packaged in microemulsions to increase bioavailability, solubility, and penetration [25]. Quercetin is formed in liposomes using dipalmytoyl-phosphatidylcholine and lecithin that increases solubility, bioavailability, and anti-tumor and antioxidant properties [7]. *Origanum dictamnus* extract contains anti-oxidant and anti-microbial substances due to large amounts of coumarin and flavones, which are formed into liposomes to increase their activity [26].

Encapsulation, which protects phytoconstituents, can be used to reduce the instability of the active ingredient, retard its degradation, and increase activity. For example, quercetin formed in liposomes with PEG in plasma has a life span exceeding five hours [27], whereas quercetin formulated in polymer nanoparticles

form demonstrates increased anti-oxidant activity, while quercetin encapsulated in Eudragite nanoparticles (polymer nanoparticles) is very stable [28].

Certain other polyphenols, such as catechin, fisetin, dehydro-silymarin, and silymarin, increase bioavailability, solubility, chemical stability, while several activities in liposome form use epikuron/Tween, dioleoyl phosphatidylcholine/PEG 2000, soybean phosphatidylcholine, lecithin, and mannitol [7].

The application of a lipid bilayer in liposomes increases catechin permeability. It occurs because of the geometric relationship between lipids in liposomes and insoluble encapsulation drugs (catechins) [7]. To date, no system has generalized the composition and encapsulation of lipids. A significant body of research has concentrated on the modification of liposome surfaces and their composition in enhancing the incorporation of insoluble drugs and well-defined target locations.

Terpenoid

Terpenoids represent the most widespread group of natural compounds, with more than 40,000 having been identified so far. In general, the structure of terpenes is formed from isoprene units with its constituent groups in the form of cyclic unsaturated hydrocarbons at varying degrees of oxygen. Terpenoids are grouped on the basis of the number of isoprene units; monoterpenes (one isoprene), sesquiterpenes, diterpenes (two isoprenes), triterpenes (three isoprenes), and tetraterpenes (four isoprenes). A variety of terpenoids have been found to have anti-cancer, anti-alzheimer [29], anti-microbial, anti-fungal, anti-parasitic, anti-allergic, anti-spasmodic, anti-hyperglycemic, anti-inflammatory, and immunomodulatory properties [30].

Monoterpenes constitute the main class of terpenoids that contain one isoprene unit found in floral aromas, plants containing essential oils, and aromatic plant resins [31], which act as anti-tumor agents. Thymoquinone is an active anti-oxidant, anti-inflammatory, and anti-cancer constituent of *Nigella sativa* [32, 33]. However, the compounds have limitations, such as poor solubility, extreme lipophilicity, and light and heat-instability that hinder pharmaceutical applications. Triterpenoids have more than 90 carbon skeletons with oxidative modification and skeleton glycosidation resulting in greater diversity [34]. Ursolic acid (UA) and oleanolic acid (OA) are natural triterpenoids obtained from no less than 120 plants. OA has hepatoprotective, anti-inflammatory, anti-hyperlipidemic, anti-tumor, and anti-viral qualities, whereas UA has anti-inflammatory, anti-hyperlipidemic, anti-hyperglycemic, hepatoprotective, anti-carcinogenic, neuroprotective, and anti-ulcer properties [35]. Their bioavailability is severely restricted by an extremely limited solubility in water.

Cucurbitacins are bitter, toxic, oxidized tetracyclic triterpenoids. These compounds can be obtained from the Rubiaceae, Cucurbitaceae, Desfontainiaceae, Scrophulariaceae, Begoniaceae, Elaeocarpaceae, Polemoniaceae, Thymelaeaceae, Primulaceae, Brassicaceae, Sterculiaceae, Datisceae, and Rosaceae families. These compounds function as heterologous chemical secretions that protect plants from external biological threats [36], and their anti-pyretic, anti-inflammatory, anti-tumor, anti-microbial, and analgesic characteristics are useful [37].

Triptolide is an epoxide diterpenoid isolated from *Tripterygium wilfordii* and useful in treating polycystic kidney diseases, pancreatic carcinoma, autoimmune, rheumatism, leukemia, and psoriasis even though this compound demonstrates poor solubility and high toxicity. Triptolide is prepared in a microemulsion system as poly [DL-lactic acid] [38] nanoparticles, which are biocompatible and biodegradable for transdermal preparations. Since one side effect of Triptolide is irritation of the gastric system, it is encapsulated in SLN to minimize this effect [39].

Cryptotanshinone is a member of the quinoid diterpene class contained in the root of *Salvia miltiorrhiza* Bunge and has applications as an anti-inflammatory, anti-bacterial, cytotoxic, anti-oxidative, anti-angiogenic and anti-parasitic, but has poor bioavailability due to water solubility. The bioavailability of cryptotanshinone administered orally will increase when prepared in solid nano lipid formulation [40].

Thymoquinone is a monoterpene extracted from *Nigella sativa* seeds that have anticancer properties [41], poor solubility, and strong hydrophobicity. The preparation of an encapsulating thymoquinone formula with polymers [42], liposomes [43], and cyclo-dextrin [44] can overcome this problem.

Alkaloid

The structural framework for alkaloids containing nitrogen atoms as part of the heterocyclic ring structure supports significant biological activity, for example, ephedrine for asthma, morphine for analgesics, and vinblastine as an anticancer treatment. The alkaloids, vinblastine, vincristine, and vinorelbine disrupt the microtubule network, causing metaphase capture in dividing cells [45], allowing for the preparation of a controlled release formulation that would endure for a long time. However, these compounds have side effects that include hematological toxicity, wheezing, dyspnea, vomiting, nausea, constipation, fever, chest pain, and tumors. Investigators have recently reported that the application of liposome nanocarrier preparations of vinca alkaloids alleviates these side effects [45, 46].

Tetrandrine is a bis-benzylisoquinoline alkaloid that induces anti-tumor activity and constitutes a non-selective calcium channel blocker. Since this compound has poor water solubility, its incorporation into the SLN system [47] can improve the formula. Paclitaxel in the gelatin nanoparticle formula is an extremely effective treatment for bladder cancer because the release rate of the active ingredient and its solubility in aqueous media becomes easier [38]. This active ingredient has been certified by the FDA as an effective and non-toxic cancer treatment marketed under the tradename Abraxane.

Anabasine is a piperidine alkaloid derived from the highly toxic *Nicotiana glauca* tree but whose toxicity decreases after formulation with supramolecular nano-encapsulation [48]. Trigonelin is introduced into the chitosan nanoparticles through the formation of an ion complex between the trigonelin's anionic carboxylic acid group and the chitosan cationic amine group to form particles less than 500 nm in size, which inhibit tumor cell invasion [49].

The Epiisopiloturine in *Jaborandi epiisopiloturine* leaves affects adult and young *Schistosoma mansoni* in addition to their eggs and is difficult to dissolve. Therefore, the structure of the liposomes is induced to increase solubility through the addition of dipalmitoylphosphatidylcholine (DPPC)/cholesterol.

Anthraquinone

Anthraquinone constitutes a group of secondary metabolite compounds that occur in abundance in natural materials. Anthraquinones are quinone derivatives of anthracenes with a basic structure of 9,10-anthraquinone dicetone. The presence of methoxyl, methyl, hydroxyl, and carboxyl groups attached to the core structure of 9,10-anthracenedione produces anthraquinone derivatives, which have a wide spectrum of medicinal properties [50].

This group contains the largest number of natural pigments, including 700 compounds, 200 of which are isolated from plants (roots, rhizomes, fruits, and flowers), while the rest are derived from mosses and fungi [51]. They are widely employed due to their anti-tumor, anti-inflammatory, diuretic, antiarthritic, antifungal, antibacterial, antimalarial, antioxidant, and laxative properties [52].

Hypericin, a naphthodianthrone (anthraquinone) compound that is a natural photosensitizer, demonstrates high hydrophobicity but limited solubility. The formulation of hypericin solid lipid nanoparticle (Hy-SLN) and the hypericin polymeric nanoparticle suspension is evolved to acquire preferable photodynamic and photoprotection [53].

Photodynamic therapy has many drawbacks, including poor water solubility and photosensitizer drug toxicity; thus anthraquinone derivatives derived from biotechnology and prepared classic nanocapsule formulations containing polycoating (PLGA) are capable of increasing photosensitizer cell uptake while also being non-toxic [54].

Radix rhei contains less efficient rhein, chrysophanol, physcione, emodin, and aloemodin. These compounds are formulated in the form of liposomes by ethanol injection method with the result that the entrapment efficiency of the liposomal encapsulation is high [55].

NANOTECH FOR THE DELIVERY OF DIFFERENT PHYTOCONSTITUENTS

The problems faced with regard to herbal formulations are those of moderate solubility in water, poor bioavailability, instability, and toxicity. Nanotechnology is effective in overcoming a number of the difficulties arising from the use of both synthetic and natural drug molecules. This technology has produced acceptable formulas, such as embedded active phytochemicals. Various nanoparticle systems such as encapsulation in the nanocarrier system and the deliverance of active compounds have been applied to support formulations. The different kinds of nanoparticles are dendrimers, solid lipid nanoparticles, liposomes, inorganic nanoparticles, microemulsions, polymer nanoparticles, and nanoflora, among others. This combination of technologies is able to achieve the last stage of active compound examination, thus enhancing the healthcare system.

Nano/submicro medicines ranging in size from 1 to 1000 nm, including liposomes, microspheres, solid lipid nanoparticles, nanoemulsions, and microemulsions (Fig. 1), are frequently employed as herbal medicines, both topically and systemically [56]. This system features controlled hydrophobic and hydrophilic drug delivery, high drug-carrying capacity, superior stability [56, 57], higher surface area proportional to volume [57, 58], and has a small size that supports high skin interactions, increases skin penetration and extends the turnover number of molecules to the targeted sites through active targeting [57,59,60]. Numerous nanoparticle systems composed of biodegradable and biocompatible materials can be applied to encase toxic drugs and transport them to specific sites around the body.




Fig. (1). Overview of nano/sub-microcarriers in herbal medicine [59].

Liposome

Liposomes are tiny vesicles consisting of one or more concentric lipid bilayers (phospholipids) between which an aqueous medium is present. The name 'liposome' is derived from the Greek terms, 'lipo', which means 'fat' and 'soma,' which translates as 'body.' Therefore, liposomes are described as round objects which are predominantly composed of lipids. Liposomes are categorized as cationic, neutral, or anionic because of their type of surface charge. Variations in shape, size and amount of lamellae contained in liposomes lead to their respective classification as unilamellar liposomes (ULs), small unilamellar vesicles (SUV, 25–100 nm), multilamellar vesicles (MLV), large unilamellar vesicles (LUV, 100 nm to 1 μm), multivesicular vesicles (MVV). Liposomes are easily produced by disrupting the lipid membrane in an aqueous medium through a sequence of extrusion (sonication) processes combined with a freezing-thaw process.

Liposomes demonstrate strong biocompatibility and can improve physicochemical characteristics in pursuance of their lipid contexture and value. Vesicles are obtained from natural phospholipids that surround the water core. Liposomes are capable of trapping both hydrophilic and lipophilic medications in the aqueous phase and lipidic bilayer with the result that lipophilic drugs will be highly efficient given the integrity of the membrane bilayer [33]. Plants and phytoconstituents that have been formulated using a liposome system can be seen in Table 1.

Table 1. Liposome in several plants [4].

| Plants | Carrier system | Methods | Effects |
|-------------------------------------|---|----------------------------------|--|
| Cratylia mollis lectin | Soybean-phosphatidylcholine, cholesterol, and stearylamine | Positively charged surfaces | Degraded toxicity and escalated antitumor activity |
| Quercetin | Egg phosphatidylcholine & cholesterol | Negatively charged surfaces | Efficiency is between 60%–80% |
| Silymarin | Lecithin and cholesterol | Reverse evaporation | Improved bioavailability and absorption |
| Breviscapine | Phosphatidylcholine, cholesterol, phosphatidylglycerol and triolein/tricaprylin | Double emulsification | Prolonged sustained delivery |
| Camptothecin | 3,5-bis (dodecyloxy) benzoic (PO)-polyethylene glycol | Coating the surface | More efficient |
| <i>A. arborescens</i> essential oil | Hydrogenated and non-hydrogenated soy phosphatidylcholine | Positively charged MLVs and SUVs | A great ability to entice EO (60%-74%) |

Liposomes play an important role as a drug carrier system because they can encapsulate polar and non-polar compounds, are stable, have a lengthy shelf life, are manageable, and their biocompatibility and degradability can be regulated. Specific disadvantages of liposomes are their short half-lives and their vesicle integrity being unsuitable for non-polar drugs. Phytosomes are phospholipids of nanoparticles covalently attached to phytochemicals [61].

Liposomes are flexible because they have a lipid structure that can be adjusted to drugs and a surface that can be converted for a specific target and time. The composition is adjusted to increase drug solubility within the encapsulation system [7].

Microemulsion

Microemulsion (ME) constitutes a fluid system consisting of a simple, transparent emulsion with alcohol or medium chains (hexanol, pentanol) dissolved in an aqueous medium and including surfactants produced by the titration method. The presence of surfactants makes the system conditions thermodynamically stable with internal phase droplets at the nanoscale (10-100 nm). The active ingredients in the ME system will become distinct from the dispersion medium *via* the membrane or interface and transferred to an environment that can improve solubility, modular stability, and bioavailability profile. The increased solubility and stability of ME are capable of delivering active constituents with different levels of lipophilic/hydrophilicity in the same formulation [62].

An example of the use of microemulsions is that of the triptolide compound contained in the vine *Tripterygium wilfordii* Hook. f (Celastraceae). This plant has anti-inflammatory, anti-neoplastic, anti-fertility, and immunosuppressive properties, but its water solubility is very poor, and it is toxic. It is formulated in isopropyl myristate TP as oil phase, aqueous water phase, and Tween 80: 1,2-propylene glycol as surfactant: co-surfactant in order to increase the permeation profile and anti-inflammatory test [63]. In addition, *Syagrus romanzoffiana* (Cham.) Glassman (Arecaceae) pulp extract is formulated in an o/w nanoemulsion system with squalane as an oil phase and a couple of ethoxylated surfactants with oleic alcohol as non-ionic surfactant, which can increase its antioxidant activity.

Solid Lipid Nanoparticles and Nanostructured Lipid Carriers

Solid lipid nanoparticles (SLN) are colloid vehicle systems (50–1,000 nm) containing pure triglycerides and are combined with other colloid systems (emulsions, liposomes, and polymer nanoparticles) to eliminate shortages of active ingredients [64]. SLN has high physicochemical stability and provides protection against the degradation caused by labile drugs [65]. The resulting structures of this system are solid lipids or mixtures, which are stabilized by surfactants [66].

The nanostructured lipid carrier (NLC) is a colloid system that comprises a lipid and solid-phase mixture to form an irregular liquid lipid matrix, increase the encapsulation efficiency, and minimize the active particle excretion during encapsulation [67]. The solid lipid phases of the NLC system feature glyceryl dilauric, stearic acid, hydrine, cetyl alcohol, and glyceryl monostearate, while the liquid phases involve caprylic/capric acid, oleic acid, and glyceryl monodicaprylic. Generally, the manufacture of NLC systems requires 5% of the active ingredient to form part of the initial precursor mixture in order to produce a drug efficiency of approximately 3%-4% orally and 70% topically [68].

The methods of SLN and NLC formulation include high-pressure homogenization (HPH), emulsification-sonification, microemulsions, and solvent evaporation-emulsification techniques.

- HPH method involves melting the lipids so that the medicine is homogeneously dispersed in the liquid lipid. It is subsequently added to the hot surfactant solution and homogeneously dispersed (pre-emulsified) by means of a sharp mixer. The nanoemulsion is then cooled at room temperature to form crystals. The cold HPH method is the same as its hot counterpart, but the crystallization process uses liquid nitrogen, rendering this technique safe for hydrophilic or thermolabile drugs.

- The emulsification-sonification method involves dissolving the active ingredient in a thawed solid lipid, adding a warm water surfactant solution, and, finally, dispersing it homogeneously using a high shear mixer. The oil emulsion formed is separated using a sonicator probe according to the nanoemulsion size and then cooled.
- The microemulsion method dissolves the active ingredient in solid lipid and aqueous surfactant/cosurfactant solution that is added during light agitation to produce a clear microemulsion. It is then dissolved in cold water (2-10°C) through light agitation and immediately crystallized to form SLN.
- The solvent-evaporation-emulsifying method works by dissolving lipids in an organic solvent, such as chloroform/cyclohexane, and emulsifying them with aqueous surfactants under continuous stirring.

The results of the utilization of nanostructured lipid carriers and solid lipid nanoparticles in several plants are mentioned in Table 2.

Table 2. Nanostructured Lipid Carriers and Solid Lipid Nanoparticles in several plants [4].

| Constituents | SLN/NLC formulation | Methods | Effects |
|--|--|-----------------------------------|--|
| Quercetin | SLNs (glyceryl monostearate, & soy lecithin) | Emulsification-sonification | Controlled release, increases bioavailability fivefold and enhances absorption within the intestines |
| | SLNs (glyceryl dibehenate & oleic acid) | Microemulsification | Increases efficiency (92.33%), stability and oral bioavailability |
| | NLCs (glyceryl monostearate, stearic acid, & soy lecithin) | Emulsion evaporation-sonification | Promotes permeation, increases the number of substances that resist in both epidermis and dermis, and enhances anti-inflammatory and anti-oxidant activities |
| | NLCs | Probe ultrasonication | Excellent stability |
| Triptolide (<i>Tripterygium wilfordii</i>) | SLNs (tristearin glyceride & stearic acid) | Microemulsification | Improves solubility and absorption into the skin. |
| Camptothecin | SLNs (cetyl palmitate & polysorbate 80) | Microemulsification | Increases bioavailability |
| Curcuminoid | SLNs (stearic acid and glyceryl monostearate) | Microemulsification | Improves stability |

Inorganic Nanoparticles

Inorganic nanoparticles are present in inorganic compounds such as ceramics, silver, carbon, and gold. These systems are classified as follows:

- Transition metal nanoparticles (Au, Ti, Pt)
Transition metals serve as medications in cases where excitation by a radiance occurs, which damages DNA and/or modifies proteins, increases lipid peroxidation, and destroys the cell microenvironment causing death. This method can be utilized for the treatment of cancer, carriers of site-specific toxic drugs [69], and potent catalysts.
- Ceramic nanoparticles (oxides, nitrides, and carbides with silica)
The system can be used as a hollow or core-shell coated with a biodegradable and biocompatible polymer that enhances targeted delivery properties.
- Carbon nanoparticles.

Liquid Crystalline Systems

Liquid crystal (LC) is a distinct phase between crystalline solid and isotropic liquid (mesophase) in the condensed structure. Mesophases, being cubic or hexagonal, are classified into lyotropic liquid crystals (LLCs) and thermotropic liquid crystals (TLC) [70]. TLC is a mesophase molecule that requires a specific temperature to be converted into an isotropic liquid. On the other hand, LLC is an amphiphilic molecule micelle with a tiny polar oxtail (hydrophilic) and a large apolar oxtail (hydrophobic). Mesophase can be identified using low-angle X-ray scattering (SAXS), low-angle neutron scattering (SANS), cryofracture electron microscopy, neutron diffraction, and reflected light microscopy [71].

LC application of herbal medicine is highly advantageous because it is stable, and interacts easily and optimally with specific targets to create a reliable, effective, and safe drug delivery system, whose distribution is even with the selected administration route and has minor side effects [72]. Vegetable oil is the most useful plant component for the development of this LC system because of its low molecular weight and poor viscosity. Vegetable oils produce low occlusion leading to their easy penetration in the skin and increased loading of therapeutic agents [73].

Santos and Rocha-Filho proved the effect of carbon bond length and the number of ethylene oxide groups on the stability of the nonionic emulsion in vegetable oils and recommended the use of such oils derived from apricot (*Prunus armeniaca*), pequi (*Caryocar brasiliense*), avocado (*Persea americana*), cupuassu (*Theobroma grandiflorum*), Brazil nuts (*Bertholletia excelsa*), mari-gold (*C. officinalis*),

andiroba (*Carapa guyanensis*), passion fruit (*Passiflora edulis*), and Buriti (*Mauritia flexuosa*). For the LC lamellar crystal stage, polyoxyethylene stearyl ether (Steareth-2; HLB: 4.7) and polyoxyethylene cetyl stearyl ether (Cetareth-5; HLB: 9.2) acted as surfactants and distilled water as the waterphase. Liquid crystal systems can be used to overcome formulation limitations in plants and phytoconstituents (Table 3).

Table 3. Liquid crystalline systems in several plants [4].

| Plants | Carrier System | Methods | Effects |
|---|---|--------------------------------------|---|
| Andiroba (<i>Carapa guyanensis</i> Aubl.) | <ul style="list-style-type: none"> • Oily phase: dicetyl phosphate, cetearyl alcohol, ceteth-10 phosphate • Aqueous phase: distilled water & PEG-12 Dimethicone | Silicone (surfactant) | Formulation viscosity, or rheological stability |
| Peach essential oil (<i>Prunus persica</i>) | LCs | Oil in water emulsions (o/w) | Improve physical stability |
| Annatto oil (<i>Bixa orellana</i>) | <ul style="list-style-type: none"> • Aqueous phase: Distilled water • Surfactant: oleth-20 | Hydrophilic/lipophilic balance (HLB) | Constructs LC |
| Marigold oil (<i>Calendula officinalis</i>) | <ul style="list-style-type: none"> • Aqueous phase: Distilled water • Surfactant: nonionic | HLB | Stable formulation |
| Marigold oil (<i>C. officinalis</i>) | <ul style="list-style-type: none"> • Aqueous phase: Distilled water • Surfactant: polyoxyethylene alkyl/stearyl ethers | Lamellar LC phases | Stability |

POLYMER NANOPARTICLES

Polymer nanoparticles are polymer-based formulations whose biodegradability and biocompatibility render them suitable as drug delivery systems because they are easy to control and target [74]. The colloid system of nanoparticles acts as a vector to manage the drug delivery and target it on a specific location. This system can escalate constituent solubility, reduce the therapeutic dose, and improve the absorption of its active components. This system can be applied to the blood because it involves non-activate neutrophils, is steady, non-immunogenic, non-toxic, non-thrombogenic, non-inflammatory, and avoids the reticuloendothelial route. Natural ingredients are produced in this system because of their ability to provide several active compounds with a similar carrier, supply a continuous delivery system, and reduce side effects.

Polymer nanoparticles fall within a diameter scale of 10–1,000 nm to facilitate the release of active substances to the target, increase bioavailability, and mitigate side effects [75]. The shape of the nanoparticles is differentiated according to their composition and structural organization in the form of nanocapsules (NCs) and

nanospheres (NSs). NCs have an oil core and are encased in a polymeric membrane which soaks up the active constituents before they are dispersed throughout the oil base. NSs have a polymer structure that retains or absorbs the active ingredients. The types of polymers widely applied are copolymers with glycolic acid (PLGA) and poly-L-lactic acid (PLA) [76].

The polymer nanoparticle method is categorized as a dispersed monomer method using alkyl cyanoacrylate, *in situ* polymerization method, and polymer deposition methods using poly(lactic acid-co-glycolic)/PLGA, acrylic/methacrylate esters, poly-caprolactone/PCL, poly(lactic acid)/PLA, and methacrylic acid copolymers (Table 4). The product obtained through the application of these three methods is the aqueous colloid suspension, which has the disadvantage of experiencing precipitation and being physicochemically unstable. This can be overcome by sublimation (freeze-drying) which dehydrates the substance and prevents particle aggregation [74]. Physicochemical characterizations such as morphological assessment, particle size, molecular weight allocation, zeta potential, pH establishment, drug dose in nanostructures, drug delivery kinetics, and long-term stability should be carried out after nanoparticles have been formulated.

Table 4. Polymer Nanoparticles in several plants [4].

| Plant/Constituents | Parts | Carrier System | Effects |
|--|--------------|--|--|
| <i>Phytolacca decandra</i> | Root | PLGA-encapsulated forms (NPD) | Bioavailability is increased, and optimum chemopreventive treatment of lung cancer initiated |
| <i>Ocimum sanctum</i> | Leaves | Sodium alginate chitosan nanoparticles (OSN) | More effective and durable antimicrobial activity |
| <i>Curcuma longa</i> (curcumin) | Rhizome | poly(ethylene glycol) monoacrylate, N-vinyl-2-pyrrolidone, and N-isopropylacrylamide | A significant measured distribution of 50 nm is easily dispersed in aqueous media. |
| | | Encapsulated in PLGA nanospheres | The encapsulation effectiveness is 90.88%, the average particle size is 45 nm and is dissolved in an aqueous without surfactant. |
| <i>Magnolia officinalis</i> (honokiol) | Bark, leaves | HN-loaded polymeric nanoparticles | Low hydrophobicity and free HN |
| <i>Gelsemium sempervirens</i> J. St.-Hil (coumarin) | Leaves | Polymeric nanocapsules | Enhanced bioavailability to that of the free active constituent |

(Table 4) cont....

| Plant/Constituents | Parts | Carrier System | Effects |
|---|---------|--|---|
| <i>Harungana madagascariensis</i> Lam. Ex Poir | Leaves | Poly (D,L-lactide-co-glycolide) (PLG) nanoparticles | Bacterial growth is reduced |
| <i>Cuscuta chinensis</i> Lam. | Seed | Nanosuspension | Antioxidant activity is increased |
| <i>Ginkgo biloba</i> (quercetin) | Leaves | <ul style="list-style-type: none"> • Polyvinyl alcohol (PVA) • Eudragit® E (EE) of Nanoprecipitation | Improved yield and the efficiency of encapsulation exceeds 99%. |
| <i>Camptotheca acuminata</i> Decne (camptothecin) | Bark | Hydrophobically modified glycol chitosan (HGC) | Loading efficiency exceeds 80% |
| <i>Polygala senega</i> | Rhizome | Encapsulated by PLGA. | Bioavailability is increased |

Dendrimers

Dendrimers are branched macromolecules with a highly symmetrical/regular nano-size and a structure both homogeneous and monodispersed. Dendrimers are also described as nano-sized globular molecules possessing unique 3D shapes Fig.(2), characterized by low dispersity and multivalence with compositions that can be modified according to the desired purpose. Their structure is divided into core, branched repetitive unit layers, and corona. This drug delivery system is preferred due to its flexibility, shape, functional group, size, and a number of generations. Moreover, it is highly attractive [77].




Fig. (2). 3D dendrimer shapes [78].

The mechanism of dendrimer release in drug administration involves the following sequence: (1) drug molecules are trapped in the dendrimer cavity precipitating an increase in hydrophobic molecule solubility, (2) drug molecules are conjugated with functional groups on the outer shell and their delivery rate is controlled. This system has advantages such as the ability to increase the diameter linearly and to

achieve a rounder shape [76]. In addition, dendrimers can prevent A β peptide fibrillation by blocking aggregation. This is evidenced by Wasiak *et al.* by modifying the aggregation of A β peptide and MAP-Tau protein in cationic phosphorus dendrimers [78]. Both peptides are the main conducive agents for DA. The presence of a desiccant in the dendrimers system may also reduce the toxicity of aggregated A β peptides. The formulation of nanoparticles of phytoconstituents can be seen in Table 5.

Table 5. Nanoparticle formulation on phytoconstituents [79].

| Phytoconstituents | Nano/Submicrocarriers | Effects |
|-------------------|--------------------------------|---|
| Curcumin | SLNs | Oral bioavailability is more effective |
| Curcuminoids | SLNs | The release of curcuminoids as anticancer and antioxidants is prolonged. |
| Quercetin | Solid lipid nanoparticles SLNs | Five times greater QU-SLN bioavailability |
| | NLCs | NLCs have a prolonged-release, and high potency for the dermal release system. |
| | Liposomes | Antioxidant activity is increased, and the drug release is 74 times higher. |
| Glycyrrhizin acid | Nanoparticles | The bioavailability of anti-inflammatory and antihypertensive activity is improved. |
| Taxel | Nanoparticles | Continuous blood circulation and huge accumulation in tumors. |
| Camptothecin | Nanoparticles | Anticancer activity is improved. |
| Berberine | Nanoparticles | Sustained drug release and anticancer activity (Fukuda). |
| Silymarin | Liposome | More effective than silymarin suspension |
| Artemisinin | Nanocapsule | Anticancer activity |

THERAPEUTICAL APPLICATION

Nanoparticle drug formulation development has proved beneficial in the treatment of several diseases such as cancer, AIDS and HIV, in addition, to advances in nutraceutical delivery and diagnostic testing. Nanoparticle size varies from 100 to 500 nm. Nanoparticles can be improved to become intelligent systems, excellent therapeutic and imaging packaging agents, and assuming stealth properties by manipulating the size, surface characteristics, and materials used. This system can conduct drugs to the target tissues and provide controlled-release therapy according to a continuous target in order to reduce the degree of drug toxicity and improve patient compliance [80].

Cancer

Cancer is a complex disease that is difficult to cure due to the ability of malignant cells to divide and multiply rapidly and uncontrollably. The types of cancer therapy commonly administered to patients, both through drugs and chemotherapy, produce side effects that destroy normal cells such as those in the intestinal epithelium and hair follicles [81]. Nanoparticle development offers the prospect of a breakthrough in chemotherapy through medication delivery to the site of a tumor or a specific cell group to prevent toxic impact on another healthy organ and other tissues [82]. Micelles represent the optimum means of dissolving an insoluble drug because the nucleus is hydrophobic while the shell is hydrophilic. The PEGylated micelle surface enhances the ability of the nanocarrier to pass through tumor blood vessels and inflamed tissue by passive transport, thereby delivering a higher dose of tumor therapy. Examples of polymer micelles, including anti-cancer medications are NC-6004, NK105, NK012, NK911, SP1049C [83], and Genexol-PM [84].

Dendrimer system-based nanoparticle therapy can increase the cytotoxic drug therapeutic index through the use of biocomponents and the reduction in PEGylation, glycosylation, acetylation, and various amino acids [85, 86]. Nanoparticles, namely carbon nanotubes (CNTs), contain allotropic forms of carbon with a cylindrical frame and a number of sheets in concentric, which can be categorized as carbon nanotubes with associated walls (SWCNTs) and multiwalled carbon nanotubes (MWCNTs) [87, 88]. Carbon nanotubes have a highly hydrophobic hollow interior through which water-insoluble medications can easily pass.

Rheumatoid

¹⁶ Rheumatoid arthritis (RA) is an autoimmune inflammatory disease of the joints due to persistent polycarticular inflammation in synovial tissues, which causes progressive deterioration of the articular cartilage and bone [89]. RA occurs due to both genetic and environmental factors [90] and an abnormal immune response leading to synovial inflammation and joint damage.

Currently available pharmaceutical drugs are administered *via* conventional dosage forms and provide therapeutic advantages to only a suboptimal level, thus posing challenges and barriers to the treatment of RA. This requires a new drug delivery strategy design for the development of a useful, targeted and safe drug delivery system with enhanced therapeutic performance [89, 91]. Nanomedicines can act as the carriers of drug delivery for effective RA management because they have unique drug delivery characteristics and are considered a very promising alternative to conventional drug therapy [92]. Among the several available RA

drug delivery routes, topical nanomedicines are more advantageous because of their greater skin retention ability, targeted specific actions, reduced drug doses, lower side effects, increased acceptance, and higher patient adherence [91].

Oral administration of pomegranate extract is an effective treatment for cartilage damage because the extract contains ellagitannins, quercetin, ellagic acid, gallic acid, and polyphenols [93], which support downregulatory activities against JNK-MAPK and NF- κ B. Thymoquinone (TQ) from *Nigella sativa* seeds has been shown to produce beneficial effects on inflammatory disorders including IBD, RA, and osteoarthritis [94] through the inhibition of serum IL-1 β and TNF- α levels in RA [95]. Resveratrol is a natural polyphenol compound obtained from grape skin (*Vitis vinifera*) and Polygonum cuspidatum root. Intra-articular resveratrol injection has been demonstrated to have potent effects against arthritis by slowing IL-1-induced apoptosis, ROS, tumor protein (p53), LTB-4, PGE2, and MMPs in animal models [96]. Hesperidin is a citrus flavonoid reported to have therapeutic benefits *vis-a-vis* arthritis through the inhibition of secondary leg swelling and downregulation of TNF- α production, IL-1, and IL-6 [97]. Curcumin is a tetraterpenoid obtained from *Curcuma longa*, which has anti-inflammatory, antioxidant, and anticancer properties [98]. Green Tea Extract (GTE) produces antiarthritic effects due to the presence of nontoxic epigallocatechin-3 gallate (EGCG) through the inhibition of IL-1-induced delivery of glycosaminoglycans and nitric oxide synthase stimulated by IL-1 (iNOS), nitric oxide, and JNK action [99]. Celastrol is a pentacyclic triterpene of *Trypterygium wilfordii* and has antitumor and anti-inflammatory effects through the downregulation of caspase-1 and inhibition of NF- κ B activation [100]. Gambogic acid (GA) is a polyprenylated xanthone containing resin derived from *Garcinia hanburyi* and *Garcinia Morella* as an antiarthritic molecule by inhibiting the secretion of IL-1 β and TNF. Synomenine is an alkaloid obtained from *Sinomenium acutum*. It is effective for RA therapy by suppressing IL-6, MMP-2, and MMP-9 in an animal model of rheumatism [101]. Centella asiatica contains asiaticoside, madecassoside, centelloside, and asiatic acid (triterpenoids), which are active as anti-inflammatory [102].

The consolidation of phytoconstituents like resveratrol, gambogic acid, thymoquinone, selastrol, hesperidin, curcumin, and polyphenols in a dose-dependent manner has great potential in RA pharmacotherapy through inflammatory mediators such as cytokines, NF- κ B, nitric oxide (NO), chemokines, arachidonic acid (AA), adhesion molecules, and lipoxygenase (LOXs). Phytoconstituents have several limitations, such as non-uniform dosage, poor bioavailability, higher metabolism, and greater distribution characteristics. Limited data is available on the concentration of polyphenols in human tissue [103], *i.e.*, 2-20%. The majority of polyphenols are metabolized directly by methylation,

glucuronidation, sulfation, and elimination by the liver, resulting in low bioavailability [103]. Oral administration of cumin causes low plasma levels as opposed to intravenous administration [22]. Resveratrol is metabolized by the small intestines, with its rapid metabolism [104] being detected in serum and plasma at a concentration of 491 90 ng/ml. Quercetin is detectable in plasma in glucuronides and sulfates unconjugated forms [105]. Herbs for RA have limited solubility and permeability, which have a higher metabolism, and have both unsuitable doses and poor bioavailability [104, 105]. This bioactive incorporation has low water solubility and high metabolism. These drawbacks can be overcome by using nano/submicrocarrier-based drug delivery technology, which maximizes increased bioavailability, greater stability, and greater efficacy without systemic side effects [91].

To overcome the limitations of curcumin, solid lipid nanoparticles are used to effectively lower leg volume through the regulation of the oxide-inflammatory cascade and immunomodulators [106]. The development of proniosomes containing curcumin (curcumin incorporated into a nanoemulsion gel) by the transdermal route can increase skin permeation fourfold [107]. Poly (lactide-c-glycolide) (PLGA) polymer-assisted nanoparticles on thymoquinone increase the entrapment efficiency to 97.5 [108]. Microemulsion-based hydrogel on synomenine is able to suppress leg swelling through the inhibition of TNF- α , IL- 1, and PGE₂ [109]. Total paeony glucoside (TGP) incorporated into the microemulsion can increase poor oral bioavailability (3-4%) [110], leading to stability in GIT [111]. The development of nanosphere-based hydrogels and solid lipid nanoparticles in Tetrandrine has been proven to increase effectiveness [112]. In addition, the ethosome of this compound has a skin permeation of 2.1 times higher than its liposome form [113]. *Tripterygium wilfordii* Hook F (TWHF) containing triptolide (TP) is incorporated into a microemulsion based hydrogel to increase its narrow therapeutic index [114]. The medical nano/submicrons loaded in the phytoconstituent to reduce limitations in RA therapy are mentioned in Table 6.

Table 6. Nano/submicron loading to reduced limitations on RA therapy [91].

| Phytoconstituents | Nano/submicrocarriers | Remarkable Effects |
|-------------------|---------------------------|---|
| Curcumin | Solid lipid nanoparticles | Extremely effective for the treatment of arthritis in rats by significantly reducing paw volume through the down-regulation of oxide-inflammatory and immune-modulatory cascade |
| | Nanoemulsion gel | Fourfold higher skin permeation and skin retention compared to curcumin solution in oil |
| | Proniosomes | Higher permeation through rat skin detected. |

(Table 6) cont....

| Phytoconstituents | Nano/submicrocarriers | Remarkable Effects |
|----------------------------------|------------------------------|--|
| Thymoquinone | Polymeric nanoparticles | 97.5% entrapment efficiency (EE) is achieved. Furthermore, higher potency as compared to thymoquinone alone is obtained. |
| Sinomenine | Microemulsion-based hydrogel | Greater beneficial effects are produced by suppressing paw swelling through the inhibition of TNF- α , IL-1, and PGE ₂ |
| Total glucosides of paeony (TGP) | Microemulsion | Bioavailability and stability-related problems are overcome by micro-emulsion, which also enhances drug stability in GIT and absorption |
| Tetrandrine | Nanospheres-based hydrogel | Absorption enhanced |
| | Solid lipid nanoparticles | Absorption enhanced |
| | Ethosomes | 2-to-1 higher skin permeation in comparison to liposomes |
| Triptolide (TP) | Microemulsion-based hydrogel | High efficacy against RA is achieved. Furthermore, no significant toxicity was discovered during the study. |
| | SLNs | Rat paw volume is significantly reduced, and a protective effect against hepatotoxicity is achieved |

Nutraceutical Delivery

Nutraceuticals are standardized components derived from food and consumed as a complement to allopathic therapies, which provide additional health benefits and reduce the risk of chronic disease [115]. The bioavailability and efficacy of nutraceuticals administered orally are influenced by the interaction of the matrix with food, their solubility in water, epithelial permeability, and degradation/metabolism [116]. They are lipophilic molecules that are soluble in fat (A, D, E, and K), and polyunsaturated lipids. Nanoparticle formulations in nutraceuticals [116, 117] can reduce their limitations, enabling their use as anti-inflammatories, antioxidants, antiapoptotic, and antiangiogenics.

The nanotechnology applications of nutraceutical preparations relate to nutrient delivery, food contact materials, nutrient bioavailability, security devices, sensor diagnostics, vitamin and mineral fortification, and nanoencapsulation of flavor and aromas [118], while a summary of the potential formulations of nutraceuticals as nanomaterials can be seen in Table 7.

Table 7. Nutraceutical formulations [118].

| Phytoconstituents | Nano/submicrocarriers | Remarkable Effects |
|--|--|---|
| Hydrophobins (Hyd)- Vitamin D ₃ | Nanoencapsulation | <ul style="list-style-type: none"> • A potential nano-transport of hydrophobic nutraceuticals to food beverage enrichment has been discovered using Hyd. • Hyd provides significant vitamin D₃ care. |
| Folic acid with whey protein and commercial resistant starch | Nanoencapsulation | Greater encapsulation efficiency increases folic acid stability. Bioactive stabilization is enhanced. |
| DL- α -tocopheryl acetate and α -carotene | Pluronic-127 and poly--caprolactone envelop nanocapsule through emulsification- diffusion method (EDM) | EDM is a promising method for the preparation of nanoparticles for use in food materials |
| Vitamin D ₃ entrapped with whey protein NPs of different calcium concentrations | Nanoencapsulation | Vitamin D ₃ with significant stability can be used in the clear beverage instead of as an enrichment agent. |
| Calcium and folic acid | Dual nutraceutical nanomaterial | To provide a good supply of nutrients important to human health |
| α -carotene, folic acid, curcumin and ergocalciferol | Protein-polysaccharide soluble nanocomplex | To intensify antioxidant activity |
| Carotenoids | Lipid nanocarriers | The high potency of clinical applications of novel delivery systems for lipophilic plant extracts |
| CoQ10 | Lipid-free nanoformulation | Effective transportation to increase the oral bioavailability of CoQ10 |
| Long-chain fatty acids and CoQ10 | Nanoemulsion | Nanoemulsion delivery systems increase the oral bioavailability of lipophilic nutraceuticals |
| Omega-3-fatty acids and oil-soluble vitamins | Biopolymeric nanogels | <ul style="list-style-type: none"> • Encapsulation and shield bioactive applied only to food-grade substance • The fabricated system remedies issues surrounding food and beverage quality |
| Curcumin | Organogel-based nanoemulsion | <p>Digestion of nanoemulsion is rapid and complete</p> <p>The oral bioavailability of curcumin improves</p> <p>Applied to dietary supplements, functional foods, and pharmaceutical industries</p> |
| α -tocopherol | Supercritical assisted nanosuspension | Improves dissolution rate, bioavailability and stability |

(Table 7) cont....

| Phytoconstituents | Nano/submicrocarriers | Remarkable effects |
|----------------------------------|--|--|
| (-)-epigallocatechin-3-gallate | Protein-polyphenol coassemblies: Lactoferrin based NPs | <ul style="list-style-type: none"> • LF-EGCG-nanoparticles and submicrometer have a purpose as EGCG protective transport to supervise other bioactive materials release. • LF-EGCG has the potency to develop food formulation based on LF as a carrier of bioactive constituents |
| Eugenol and clove oil | COM and EM oil titration-precipitation | The formulation in microemulsion provides an oral delivery system for clove oil in homogenous, water-based, and thermodynamically stable doses |
| Dextran and isoflavone genistein | Enzymatic-assisted inclusion complexation method | <ul style="list-style-type: none"> • DMSO-water inclusion protocol is more suitable for delivering genistein into enzymatically hydrolysed dextran • Increase the delivery of nutraceuticals by 11- to 141-fold due to the creation of novel H-bonds and the interaction of Van der Waals forces |

The impact of nanotechnology on modern life is both profound and powerful. The technological speed of nanomedicine use is achieved by utilizing several kinds of nanoparticles in the prevention, diagnosis, and treatment of a wide range of complex illnesses. Herbal medicines that had been previously struggled with formulation and delivery of their active ingredients are now starting to use the benefits of nanotechnology. Cosmetochem's Herbasec[®] has been launched as a liposomal standardized extract for use in cosmetics due to its antioxidant effect in preventing aging. Several other plants are also employed in the production of nanomedicines, such as white hibiscus, green tea, aloe vera, white tea, guarana, and liquorice root. There are also several naturally-produced phytochemicals used as ingredients of nanomedicines such as triterpenes in *Centella asiatica*, visnadin in *Ammi visnaga*, silymarin and Silybin in milk thistle, vhamitenosides in Hawthorn blossoms, escin β -sitosterol in horse chestnut, sericoside in *Terminalia sericea*, ginsenosides in *Panax ginseng*, polyphenols in grape seeds and green tea, ginkgo flavon glucosides, ginkgolides, and bilobalide in *Ginkgo biloba* [74]. This proves that phytoconstituents represent the future of nanotechnology related to drug delivery, and a new era of re-exploring and investigating the full potency of traditional herbs has begun. The advantages of nanoscience in analyzing herbal medicines include:

- increased solubility and bioavailability of active ingredients
- reducing the side effects and toxicity of active ingredients
- enhancing the stability of active ingredients with regard to targets

- improving the biocompatibility and reducing the toxicity of the formulations
- increasing nanoparticle safety, and the therapeutic index of the drug

CONCLUSION

Poor absorption of certain phytoconstituents because they are hydrophilic and unable to pass through cell lipid membranes can be overcome by applying nanoengineering such as phytosomes, liposomes, nanoemulsions, nanoparticles, solid lipid nanoparticles, and ethosomes in increasing solubility, bioavailability, pharmacological effect, stability, effectiveness, selectivity, and drug specificity of the bioactive constituents.

CONSENT FOR PUBLICATION

Not applicable.

CONFLICT OF INTEREST

The author declares no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

- [1] Matijevic E. *Fine particles in medicine and pharmacy*. New York: Springer 2012. [<http://dx.doi.org/10.1007/978-1-4614-0379-1>]
- [2] Vo TN, Kasper FK, Mikos AG. Strategies for controlled delivery of growth factors and cells for bone regeneration. *Adv Drug Deliv Rev* 2012; 64(12): 1292-309. [<http://dx.doi.org/10.1016/j.addr.2012.01.016>] [PMID: 22342771]
- [3] Kohane DS. Microparticles and nanoparticles for drug delivery. *Biotechnol Bioeng* 2007; 96(2): 203-9. [<http://dx.doi.org/10.1002/bit.21301>] [PMID: 17191251]
- [4] Bonifácio BV, Silva PB, Ramos MA, Negri KM, Bauab TM, Chorilli M. Nanotechnology-based drug delivery systems and herbal medicines: a review. *Int J Nanomedicine* 2014; 9: 1-15. [PMID: 24363556]
- [5] Bharali DJ, Siddiqui IA, Adhami VM, *et al.* Nanoparticle delivery of natural products in the prevention and treatment of cancers: current status and future prospects. *Cancers (Basel)* 2011; 3(4): 4024-45. [<http://dx.doi.org/10.3390/cancers3044024>] [PMID: 24213123]
- [6] Martens S, Mithöfer A. Flavones and flavone synthases. *Phytochemistry* 2005; 66(20): 2399-407. [<http://dx.doi.org/10.1016/j.phytochem.2005.07.013>] [PMID: 16137727]
- [7] Mignet N, Seguin J, Chabot GG. Bioavailability of polyphenol liposomes: a challenge ahead. *Pharmaceutics* 2013; 5(3): 457-71. [<http://dx.doi.org/10.3390/pharmaceutics5030457>] [PMID: 24300518]

- [8] Mann J, Davidson RS, Hobbs JB, Banthorpe DV, Harborne JB. Natural products: Their chemistry and biological significance. 1st ed., Longman Group UK Limited 1994.
- [9] Bruschi M, Orlandi O, Rindone M, Rindone B, Saliu F, Suarez-Bertoa R, *et al.* Podophyllotoxin and antitumor synthetic aryltetralines. Toward a biomimetic preparation. *Biomimetics learning from nature.* InTech 2010.
[<http://dx.doi.org/10.5772/8772>]
- [10] Celotti E, Ferrarini R, Zironi R, Conte LS. Resveratrol content of some wines obtained from dried *Valpolicella grapes*: Recioto and Amarone. *J Chromatogr A* 1996; 730(1-2): 47-52.
[[http://dx.doi.org/10.1016/0021-9673\(95\)00962-0](http://dx.doi.org/10.1016/0021-9673(95)00962-0)] [PMID: 8680595]
- [11] Summerlin N, Soo E, Thakur S, Qu Z, Jambhrunkar S, Popat A. Resveratrol nanoformulations: challenges and opportunities. *Int J Pharm* 2015; 479(2): 282-90.
[<http://dx.doi.org/10.1016/j.ijpharm.2015.01.003>] [PMID: 25572692]
- [12] Trela BC, Waterhouse AL. Resveratrol: Isomeric molar absorptivities and stability. *J Agric Food Chem* 1996; 44: 1253-7.
[<http://dx.doi.org/10.1021/jf9504576>]
- [13] Walle T. Bioavailability of resveratrol. *Ann N Y Acad Sci* 2011; 1215: 9-15.
[<http://dx.doi.org/10.1111/j.1749-6632.2010.05842.x>] [PMID: 21261636]
- [14] da Rocha Lindner G, Bonfanti Santos D, Colle D, *et al.* Improved neuroprotective effects of resveratrol-loaded polysorbate 80-coated poly(lactide) nanoparticles in MPTP-induced Parkinsonism. *Nanomedicine (Lond)* 2015; 10(7): 1127-38.
[<http://dx.doi.org/10.2217/nnm.14.165>] [PMID: 25929569]
- [15] Penalva R, Esparza I, Larraneta E, González-Navarro CJ, Gamazo C, Irache JM. Zein-based nanoparticles improve the oral bioavailability of resveratrol and its anti-inflammatory effects in a mouse model of endotoxic shock. *J Agric Food Chem* 2015; 63(23): 5603-11.
[<http://dx.doi.org/10.1021/jf505694e>] [PMID: 26027429]
- [16] Sessa M, Balestrieri ML, Ferrari G, *et al.* Bioavailability of encapsulated resveratrol into nanoemulsion-based delivery systems. *Food Chem* 2014; 147: 42-50.
[<http://dx.doi.org/10.1016/j.foodchem.2013.09.088>] [PMID: 24206683]
- [17] Soo E, Thakur S, Qu Z, Jambhrunkar S, Parekh HS, Popat A. Enhancing delivery and cytotoxicity of resveratrol through a dual nanoencapsulation approach. *J Colloid Interface Sci* 2016; 462: 368-74.
[<http://dx.doi.org/10.1016/j.jcis.2015.10.022>] [PMID: 26479200]
- [18] Venuti V, Cannavà C, Cristiano MC, *et al.* A characterization study of resveratrol/sulfobutyl ether--cyclodextrin inclusion complex and *in vitro* anticancer activity. *Colloids Surf B Biointerfaces* 2014; 115: 22-8.
[<http://dx.doi.org/10.1016/j.colsurfb.2013.11.025>] [PMID: 24321846]
- [19] Catania A, Barrajón-Catalán E, Nicolosi S, Cicirata F, Micol V. Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells. *Breast Cancer Res Treat* 2013; 141(1): 55-65.
[<http://dx.doi.org/10.1007/s10549-013-2667-y>] [PMID: 23959397]
- [20] Mohanty C, Sahoo SK. The *in vitro* stability and *in vivo* pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. *Biomaterials* 2010; 31(25): 6597-611.
[<http://dx.doi.org/10.1016/j.biomaterials.2010.04.062>] [PMID: 20553984]
- [21] Carvalho DM, Takeuchi KP, Geraldine RM, Moura CJ, Torres MCL. Production, solubility and antioxidant activity of curcumin nanosuspension. *Food Sci Technol* 2015; 35(1): 115-9.
[<http://dx.doi.org/10.1590/1678-457X.6515>]
- [22] Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MNVR. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. *Eur J Pharm Sci* 2009; 37(3-4): 223-30.

- [http://dx.doi.org/10.1016/j.ejps.2009.02.019] [PMID: 19491009]
- [23] Sasaki H, Sunagawa Y, Takahashi K, *et al.* Innovative preparation of curcumin for improved oral bioavailability. *Biol Pharm Bull* 2011; 34(5): 660-5.
[http://dx.doi.org/10.1248/bpb.34.660] [PMID: 21532153]
- [24] Yen FL, Wu TH, Lin LT, Cham TM, Lin CC. Nanoparticles formulation of *Cuscuta chinensis* prevents acetaminophen-induced hepatotoxicity in rats. *Food Chem Toxicol* 2008; 46(5): 1771-7.
[http://dx.doi.org/10.1016/j.fct.2008.01.021] [PMID: 18308443]
- [25] Solanki SS, Sarkar P, Dhanwani RK. Microemulsion drug delivery system: for bioavailability enhancement of ampelopsin 2012.
[http://dx.doi.org/10.5402/2012/108164]
- [26] Gortzi O, Lala S, Chinou I, Tsaknis J. Evaluation of the antimicrobial and antioxidant activities of *Origanum dictamnus* extracts before and after encapsulation in liposomes. *Molecules* 2007; 12(5): 932-45.
[http://dx.doi.org/10.3390/12050932] [PMID: 17873829]
- [27] Yuan ZP, Chen LJ, Fan LY, *et al.* Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. *Clin Cancer Res* 2006; 12(10): 3193-9.
[http://dx.doi.org/10.1158/1078-0432.CCR-05-2365] [PMID: 16707620]
- [28] Pool H, Quintana D, Figueroa J. Polymeric nanoparticles as oral delivery systems for encapsulation and release of polyphenolic compounds: Impact on quercetin antioxidant activity and bioaccessibility. *Food Biophys* 2012; 7: 276-88.
[http://dx.doi.org/10.1007/s11483-012-9266-z]
- [29] Gali-Muhtasib H, Diab-Assaf M, Boltze C, *et al.* Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells *via* a p53-dependent mechanism. *Int J Oncol* 2004; 25(4): 857-66.
[PMID: 15375533]
- [30] Thoppil RJ, Bishayee A. Terpenoids as potential chemopreventive and therapeutic agents in liver cancer. *World J Hepatol* 2011; 3(9): 228-49.
[http://dx.doi.org/10.4254/wjh.v3.i9.228] [PMID: 21969877]
- [31] Rabi T, Bishayee A. Terpenoids and breast cancer chemoprevention. *Breast Cancer Res Treat* 2009; 115(2): 223-39.
[http://dx.doi.org/10.1007/s10549-008-0118-y] [PMID: 18636327]
- [32] Kaseb AO, Chinnakannu K, Chen D, *et al.* Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. *Cancer Res* 2007; 67(16): 7782-8.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-1483] [PMID: 17699783]
- [33] Chehl N, Chipitsyna G, Gong Q, Yeo CJ, Arafat HA. Anti-inflammatory effects of the *Nigella sativa* seed extract, thymoquinone, in pancreatic cancer cells. *HPB (Oxford)* 2009; 11(5): 373-81.
[http://dx.doi.org/10.1111/j.1477-2574.2009.00059.x] [PMID: 19768141]
- [34] Kushiro T, Shibuya M, Masuda K, Ebizuka Y. Mutational studies on triterpene synthases: Engineering lupeol synthase into β -Amyrin synthase. *J Am Chem Soc* 2000; 122: 6816-24.
[http://dx.doi.org/10.1021/ja0010709]
- [35] Yang L, Sun Z, Zu Y, *et al.* Physicochemical properties and oral bioavailability of ursolic acid nanoparticles using supercritical anti-solvent (SAS) process. *Food Chem* 2012; 132(1): 319-25.
[http://dx.doi.org/10.1016/j.foodchem.2011.10.083] [PMID: 26434296]
- [36] Alghasham AA. Cucurbitacins—A promising target for cancer therapy. *Int J Health Sci* 2013; 7(1)
- [37] Lee DH, Iwanski GB, Thoennissen NH. Cucurbitacin: ancient compound shedding new light on cancer treatment. *ScientificWorldJournal* 2010; 10: 413-8.
[http://dx.doi.org/10.1100/tsw.2010.44] [PMID: 20209387]

- [38] Zhang C, Gu C, Peng F, *et al.* Preparation and optimization of triptolide-loaded solid lipid nanoparticles for oral delivery with reduced gastric irritation. *Molecules* 2013; 18(11): 13340-56. [<http://dx.doi.org/10.3390/molecules181113340>] [PMID: 24172242]
- [39] Zhang N, Wardwell PR, Bader RA. Polysaccharide-based micelles for drug delivery. *Pharmaceutics* 2013; 5(2): 329-52. [<http://dx.doi.org/10.3390/pharmaceutics5020329>] [PMID: 24300453]
- [40] Hu L, Xing Q, Meng J, Shang C. Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles. *AAPS PharmSciTech* 2010; 11(2): 582-7. [<http://dx.doi.org/10.1208/s12249-010-9410-3>] [PMID: 20352534]
- [41] Zihlif MA, Mahmoud IS, Ghanim MT, *et al.* Thymoquinone efficiently inhibits the survival of EBV-infected B cells and alters EBV gene expression. *Integr Cancer Ther* 2013; 12(3): 257-63. [<http://dx.doi.org/10.1177/1534735412458827>] [PMID: 23089554]
- [42] Ravindran J, Nair HB, Sung B, Prasad S, Tekmal RR, Aggarwal BB. Thymoquinone poly (lactide-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential. *Biochem Pharmacol* 2010; 79(11): 1640-7. [<http://dx.doi.org/10.1016/j.bcp.2010.01.023>] [PMID: 20105430]
- [43] Odeh F, Ismail SI, Abu-Dahab R, Mahmoud IS, Al Bawab A. Thymoquinone in liposomes: a study of loading efficiency and biological activity towards breast cancer. *Drug Deliv* 2012; 19(8): 371-7. [<http://dx.doi.org/10.3109/10717544.2012.727500>] [PMID: 23043626]
- [44] Abu-Dahab R, Odeh F, Ismail SI, Azzam H, Al Bawab A. Preparation, characterization and antiproliferative activity of thymoquinone- β -cyclodextrin self assembling nanoparticles. *Pharmazie* 2013; 68(12): 939-44. [PMID: 24400439]
- [45] Noble CO, Guo Z, Hayes ME, *et al.* Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. *Cancer Chemother Pharmacol* 2009; 64(4): 741-51. [<http://dx.doi.org/10.1007/s00280-008-0923-3>] [PMID: 19184019]
- [46] Zhigaltsev IV, Maurer TN, Akhong Q, *et al.* Liposome-encapsulated vincristine, vinblastine and vinorelbine: A comparative study of drug loading and retention. *Int J Mol Sci* 2012; 13: 12598-607.
- [47] Li Y, Dong L, Jia A, Chang X, Xue H. Preparation and characterization of solid lipid nanoparticles loaded traditional Chinese medicine. *Int J Biol Macromol* 2006; 38(3-5): 296-9. [<http://dx.doi.org/10.1016/j.ijbiomac.2006.03.006>] [PMID: 16600362]
- [48] Gao Y, Yang X, Wang Z, Zhong Z, Hu Y, Wang Y. Supramolecular nano-encapsulation of anabasin reduced its developmental toxicity in Zebrafish. *Front Chem* 2020; 8: 134. [<http://dx.doi.org/10.3389/fchem.2020.00134>] [PMID: 32185162]
- [49] Jeong YI, Kim DH, Chung KD, Kim YH, Lee YS, Choi KC. Antitumor activity of trigonelline-incorporated chitosan nanoparticles. *J Nanosci Nanotechnol* 2014; 14(8): 5633-7. [<http://dx.doi.org/10.1166/jnn.2014.8818>] [PMID: 25935980]
- [50] Tutin F, Clewer HWB. The constituents of rhubarb. *J Chem Soc Trans* 1911; 36: 946-67. [<http://dx.doi.org/10.1039/CT9119900946>]
- [51] Seigler DS. *Plant secondary metabolism*. Springer Science & Business Media 2012.
- [52] Chien SC, Wu YC, Chen ZW, Yang WC. Naturally occurring anthraquinones: chemistry and therapeutic potential in autoimmune diabetes. *Evid Based Complement Alternat Med* 2015; 2015: 357357. [<http://dx.doi.org/10.1155/2015/357357>] [PMID: 25866536]
- [53] Lima A, Pizzolb C, Monteirob F, Creczynski-Pasab T, Andradec G, Ribeiroc A, *et al.* Hypericin encapsulated in solid lipid nanoparticles: Phototoxicity and photodynamic efficiency. *J of*

- Photochemistry and Photobiology B. Biology (Basel) 2013; 125(1): 146-54.
- [54] Amantino CF, de Baptista-Neto Á, Badino AC, Siqueira-Moura MP, Tedesco AC, Primo FL. Anthraquinone encapsulation into polymeric nanocapsules as a new drug from biotechnological origin designed for photodynamic therapy. *Photodiagn Photodyn Ther* 2020; 31: 101815. [<http://dx.doi.org/10.1016/j.pdpdt.2020.101815>] [PMID: 32407889]
- [55] Suo XB, Liu Y, Wu YH, Li YX. [Liposomal encapsulation of free anthraquinones in rhizoma et radix rhei and its quality control]. *Zhong Yao Cai* 2010; 33(4): 614-6. [PMID: 20845793]
- [56] Aboalnaja KO, Yaghmoor S, Kumosani TA, McClements DJ. Utilization of nanoemulsions to enhance bioactivity of pharmaceuticals, supplements, and nutraceuticals: Nanoemulsion delivery systems and nanoemulsion excipient systems. *Expert Opin Drug Deliv* 2016; 13(9): 1327-36. [<http://dx.doi.org/10.1517/17425247.2016.1162154>] [PMID: 26984045]
- [57] Song F, Tang J, Geng R, *et al.* Comparison of the efficacy of bone marrow mononuclear cells and bone mesenchymal stem cells in the treatment of osteoarthritis in a sheep model. *Int J Clin Exp Pathol* 2014; 7(4): 1415-26. [PMID: 24817937]
- [58] Colmenares D, Sun Q, Shen P, Yue Y, McClements DJ, Park Y. Delivery of dietary triglycerides to *Caenorhabditis elegans* using lipid nanoparticles: Nanoemulsion-based delivery systems. *Food Chem* 2016; 202: 451-7. [<http://dx.doi.org/10.1016/j.foodchem.2016.02.022>] [PMID: 26920318]
- [59] Rahman M, Kumar V, Beg S, Sharma G, Katare OP, Anwar F. Emergence of liposome as targeted magic bullet for inflammatory disorders: current state of the art. *Artif Cells Nanomed Biotechnol* 2016; 44(7): 1597-608. [<http://dx.doi.org/10.3109/21691401.2015.1129617>] [PMID: 26758815]
- [60] Solans C, Izquierdo P, Nolla J, Azemar N, Celma MJG. Nano-emulsions. *Curr Opin Colloid Interface Sci* 2005; 10: 102-10. [<http://dx.doi.org/10.1016/j.cocis.2005.06.004>]
- [61] Kareparamban J, Nikam P, Jadhav A, Kadam V. Phytosome: A novel revolution in herbal drugs. *Int J Res Pharm Chem* 2012; 2(2): 299-310.
- [62] Sintov AC, Shapiro L. New microemulsion vehicle facilitates percutaneous penetration *in vitro* and cutaneous drug bioavailability *in vivo*. *J Control Release* 2004; 95(2): 173-83. [<http://dx.doi.org/10.1016/j.jconrel.2003.11.004>] [PMID: 14980766]
- [63] Mei Z, Chen H, Weng T, Yang Y, Yang X. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. *Eur J Pharm Biopharm* 2003; 56(2): 189-96. [[http://dx.doi.org/10.1016/S0939-6411\(03\)00067-5](http://dx.doi.org/10.1016/S0939-6411(03)00067-5)] [PMID: 12957632]
- [64] Martins S, Costa-Lima S, Cameiro T, Cordeiro-da-Silva A, Souto EB, Ferreira DC. Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. *Int J Pharm* 2012; 430(1-2): 216-27. [<http://dx.doi.org/10.1016/j.ijpharm.2012.03.032>] [PMID: 22465548]
- [65] Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. *Int J Pharm* 2009; 366(1-2): 170-84. [<http://dx.doi.org/10.1016/j.ijpharm.2008.10.003>] [PMID: 18992314]
- [66] Naahidi S, Jafari M, Edalat F, Raymond K, Khademhosseini A, Chen P. Biocompatibility of engineered nanoparticles for drug delivery. *J Control Release* 2013; 166(2): 182-94. [<http://dx.doi.org/10.1016/j.jconrel.2012.12.013>] [PMID: 23262199]
- [67] Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. *Adv Drug Deliv Rev* 2004; 56(9): 1257-72. [<http://dx.doi.org/10.1016/j.addr.2003.12.002>] [PMID: 15109768]

- [68] Puri A, Loomis K, Smith B, *et al.* Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. *Crit Rev Ther Drug Carrier Syst* 2009; 26(6): 523-80. [http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v26.i6.10] [PMID: 20402623]
- [69] Bhattacharyya S, Kudgus RA, Bhattacharya R, Mukherjee P. Inorganic nanoparticles in cancer therapy. *Pharm Res* 2011; 28(2): 237-59. [http://dx.doi.org/10.1007/s11095-010-0318-0] [PMID: 21104301]
- [70] Rossetti FC, Fantini MCA, Carollo ARH, Tedesco AC, Bentley MVLB. Analysis of liquid crystalline nanoparticles by small angle X-ray diffraction: evaluation of drug and pharmaceutical additives influence on the internal structure. *J Pharm Sci* 2011; 100(7): 2849-57. [http://dx.doi.org/10.1002/jps.22522] [PMID: 21337546]
- [71] Farkas E, Zelkó R, Török G, Rácz I, Marton S. Influence of chlorhexidine species on the liquid crystalline structure of vehicle. *Int J Pharm* 2001; 213(1-2): 1-5. [http://dx.doi.org/10.1016/S0378-5173(00)00575-5] [PMID: 11165088]
- [72] Praça FSG, Medina WSG, Petrilli R, Bentley MVLB. Liquid crystal nanodispersions enable the cutaneous delivery of photosensitizer for topical PDT: fluorescence microscopy study of skin penetration. *Curr Nanosci* 2012; 8(4): 535-40. [http://dx.doi.org/10.2174/157341312801784203] [PMID: 221952107]
- [73] Bernardi DS, Pereira TA, Maciel NR, *et al.* Formation and stability of oil-in-water nanoemulsions containing rice bran oil: *in vitro* and *in vivo* assessments. *J Nanobiotechnology* 2011; 9(44): 44. [http://dx.doi.org/10.1186/1477-3155-9-44] [PMID: 21952107]
- [74] Khuda-Bukhsh AR, Bhattacharyya SS, Paul S, Boujedaini N. Polymeric nanoparticle encapsulation of a naturally occurring plant scopoletin and its effects on human melanoma cell A375. *J Chin Integr Med* 2010; 8(9): 853-62. [http://dx.doi.org/10.3736/jcim20100909] [PMID: 20836976]
- [75] Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. *Mol Pharm* 2008; 5(4): 505-15. [http://dx.doi.org/10.1021/mp800051m] [PMID: 18672949]
- [76] Senthil KP. Nano-drug delivery system: applications in veterinary medicine and animal health. *Int J Sci Environ Technol* 2016; 5: 4447-51.
- [77] Çetin M, Aytekin E, Yavuz B, Bozdağ Pehlivan S. Nanoscience in targeted brain drug delivery. In importance and application of nanotechnology-based brain drug delivery systems. *Drug Delivery across the Blood-Brain Barrier* 2017; 117-147.
- [78] Wasiaik T, Ionov M, Nieznanski K, *et al.* Phosphorus dendrimers affect Alzheimer's (A β 1-28) peptide and MAP-Tau protein aggregation. *Mol Pharm* 2012; 9(3): 458-69. [http://dx.doi.org/10.1021/mp2005627] [PMID: 22206488]
- [79] Bhavsar S. Application of nanotechnology for phytoconstituents. *Arch Nano* 2018; 1(1): 6-7. [Review].
- [80] Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. *Saudi Pharm J* 2018; 26(1): 64-70. [http://dx.doi.org/10.1016/j.jsps.2017.10.012] [PMID: 29379334]
- [81] Baudino TA. Targeted cancer therapy: the next generation of cancer treatment. *Curr Drug Discov Technol* 2015; 12(1): 3-20. [http://dx.doi.org/10.2174/1570163812666150602144310] [PMID: 26033233]
- [82] Shen B, Ma Y, Yu S, Ji C. Smart multifunctional magnetic nanoparticle-based drug delivery system for cancer thermo-chemotherapy and intracellular imaging. *ACS Appl Mater Interfaces* 2016; 8(37): 24502-8. [http://dx.doi.org/10.1021/acsami.6b09772] [PMID: 27573061]
- [83] Oerlemans C, Bult W, Bos M, Storm G, Nijssen JFW, Hennink WE. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. *Pharm Res* 2010; 27(12): 2569-89.

- [http://dx.doi.org/10.1007/s11095-010-0233-4] [PMID: 20725771]
- [84] Zhang X, Huang Y, Li S. Nanomicellar carriers for targeted delivery of anticancer agents. *Ther Deliv* 2014; 5(1): 53-68. [http://dx.doi.org/10.4155/tde.13.135] [PMID: 24341817]
- [85] Baker JR. Dendrimer-based nanoparticles for cancer therapy. *Hematol Am Soc Hematol Educ Program* 2009; pp. 708-19.
- [86] Cheng Y, Zhao L, Li Y, Xu T. Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives. *Chem Soc Rev* 2011; 40(5): 2673-703. [http://dx.doi.org/10.1039/c0cs00097c] [PMID: 21286593]
- [87] Rastogi V, Yadav P, Bhattacharya SS, *et al.* Carbon nanotubes: an emerging drug carrier for targeting cancer cells. *J Drug Deliv* 2014; 2014: 670815. [http://dx.doi.org/10.1155/2014/670815] [PMID: 24872894]
- [88] Sanginario A, Miccoli B, Demarchi D. Carbon nanotubes as an effective opportunity for cancer diagnosis and treatment. *Biosensors (Basel)* 2017; 7(1): 9. [http://dx.doi.org/10.3390/bios7010009] [PMID: 28212271]
- [89] Anderson KO, Bradley LA, Young LD, McDaniel LK, Wise CM. Rheumatoid arthritis: review of psychological factors related to etiology, effects, and treatment. *Psychol Bull* 1985; 98(2): 358-87. [http://dx.doi.org/10.1037/0033-2909.98.2.358] [PMID: 3901066]
- [90] Scrivero R, Di Franco M, Spadaro A, Valesini G. The immunology of rheumatoid arthritis. *Ann N Y Acad Sci* 2007; 1108: 312-22. [http://dx.doi.org/10.1196/annals.1422.033] [PMID: 17893995]
- [91] Rahman M, Beg S, Verma A, *et al.* Phytoconstituents as pharmacotherapeutics in rheumatoid arthritis: challenges and scope of nano/submicromedicine in its effective delivery. *J Pharm Pharmacol* 2017; 69(1): 1-14. [http://dx.doi.org/10.1111/jphp.12661] [PMID: 27774648]
- [92] Albuquerque J, Moura CC, Sarmiento B, Reis S. Solid lipid nanoparticles: a potential multifunctional approach towards rheumatoid arthritis theranostics. *Molecules* 2015; 20(6): 11103-18. [http://dx.doi.org/10.3390/molecules200611103] [PMID: 26087258]
- [93] Rasheed Z, Akhtar N, Haqqi TM. Pomegranate extract inhibits the interleukin-1 β -induced activation of MKK-3, p38 α -MAPK and transcription factor RUNX-2 in human osteoarthritis chondrocytes. *Arthritis Res Ther* 2010; 12(5): R195. [http://dx.doi.org/10.1186/ar3166] [PMID: 20955562]
- [94] Umar S, Hedaya O, Singh AK, Ahmed S. Thymoquinone inhibits TNF- α -induced inflammation and cell adhesion in rheumatoid arthritis synovial fibroblasts by ASK1 regulation. *Toxicol Appl Pharmacol* 2015; 287(3): 299-305. [http://dx.doi.org/10.1016/j.taap.2015.06.017] [PMID: 26134265]
- [95] Ahmad A, Husain A, Mujeeb M, *et al.* A review on therapeutic potential of *Nigella sativa*: A miracle herb. *Asian Pac J Trop Biomed* 2013; 3(5): 337-52. [http://dx.doi.org/10.1016/S2221-1691(13)60075-1] [PMID: 23646296]
- [96] Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the *in vivo* evidence. *Nat Rev Drug Discov* 2006; 5(6): 493-506. [http://dx.doi.org/10.1038/nrd2060] [PMID: 16732220]
- [97] Umar S, Kumar A, Sajad M, *et al.* Hesperidin inhibits collagen-induced arthritis possibly through suppression of free radical load and reduction in neutrophil activation and infiltration. *Rheumatol Int* 2013; 33(3): 657-63. [http://dx.doi.org/10.1007/s00296-012-2430-4] [PMID: 22527139]
- [98] Funk JL, Oyarzo JN, Frye JB, *et al.* Turmeric extracts containing curcuminoids prevent experimental rheumatoid arthritis. *J Nat Prod* 2006; 69(3): 351-5.

- [http://dx.doi.org/10.1021/np050327j] [PMID: 16562833]
- [99] Ahmed S. Green tea polyphenol epigallocatechin 3-gallate in arthritis: progress and promise. *Arthritis Res Ther* 2010; 12(2): 208. [http://dx.doi.org/10.1186/ar2982] [PMID: 20447316]
- [100] Salminen A, Lehtonen M, Paimela T, Kaamiranta K. Celastrol: molecular targets of thunder god vine. *Biochem Biophys Res Commun* 2010; 394(3): 439-42. [http://dx.doi.org/10.1016/j.bbrc.2010.03.050] [PMID: 20226165]
- [101] Tong B, Yu J, Wang T, *et al.* Sinomenine suppresses collagen-induced arthritis by reciprocal modulation of regulatory T cells and Th17 cells in gut-associated lymphoid tissues. *Mol Immunol* 2015; 65(1): 94-103. [http://dx.doi.org/10.1016/j.molimm.2015.01.014] [PMID: 25656802]
- [102] Wang T, Wei Z, Dou Y, *et al.* Intestinal interleukin-10 mobilization as a contributor to the anti-arthritis effect of orally administered madecassoside: a unique action mode of saponin compounds with poor bioavailability. *Biochem Pharmacol* 2015; 94(1): 30-8. [http://dx.doi.org/10.1016/j.bcp.2015.01.004] [PMID: 25600909]
- [103] Siddiqui MZ. *Boswellia serrata*, a potential antiinflammatory agent: an overview. *Indian J Pharm Sci* 2011; 73(3): 255-61. [PMID: 22457547]
- [104] Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. *Mol Nutr Food Res* 2005; 49(5): 472-81. [http://dx.doi.org/10.1002/mnfr.200500010] [PMID: 15779070]
- [105] Morand C, Crespy V, Manach C, Besson C, Demigné C, Rémésy C. Plasma metabolites of quercetin and their antioxidant properties. *Am J Physiol* 1998; 275(1): R212-9. [PMID: 9688981]
- [106] Arora R, Kuhad A, Kaur IP, Chopra K. Curcumin loaded solid lipid nanoparticles ameliorate adjuvant-induced arthritis in rats. *Eur J Pain* 2015; 19(7): 940-52. [http://dx.doi.org/10.1002/ejp.620] [PMID: 25400173]
- [107] Kumar K, Rai AK. Proniosomal formulation of curcumin having anti-inflammatory and anti-arthritic activity in different experimental animal models. *Pharmazie* 2012; 67(10): 852-7. [PMID: 23136720]
- [108] Singh A, Ahmad I, Akhter S, Ahmad MZ, Iqbal Z, Ahmad J. Thymoquinone: major molecular targets, prominent pharmacological actions and drug delivery Concerns. *Curr Bioact Compd* 2012; 8: 334-44. [http://dx.doi.org/10.2174/1573407211208040003]
- [109] Zhang XZ, Zhu HD, Meng SF, Pan XG. [Preparation of sinomenine microemulsion and its transdermal absorption]. *Zhongguo Zhongyao Zazhi* 2007; 32(19): 2007-10. [PMID: 18161292]
- [110] Zheng YQ, Wei W. Total glucosides of paeony suppresses adjuvant arthritis in rats and intervenes cytokines signaling between different types of synoviocytes. *Int Immunopharmacol* 2005; 5: 156-73. [http://dx.doi.org/10.1016/j.intimp.2005.03.010]
- [111] Wang X, Xue M, Gu J, Fang X, Sha X. Transdermal microemulsion drug delivery system for impairing male reproductive toxicity and enhancing efficacy of *Tripterygium Wilfordii* Hook f. *Fitoterapia* 2012; 83(4): 690-8. [http://dx.doi.org/10.1016/j.fitote.2012.02.006] [PMID: 22391023]
- [112] Li S, Ji Z, Zou M, Nie X, Shi Y, Cheng G. Preparation, characterization, pharmacokinetics and tissue distribution of solid lipid nanoparticles loaded with tetrandrine. *AAPS PharmSciTech* 2011; 12(3): 1011-8. [http://dx.doi.org/10.1208/s12249-011-9665-3] [PMID: 21811889]
- [113] Fan C, Li X, Zhou Y, *et al.* Enhanced topical delivery of tetrandrine by ethosomes for treatment of

- arthritis. *BioMed Res Int* 2013; 2013: 161943.
[<http://dx.doi.org/10.1155/2013/161943>] [PMID: 24062995]
- [114] Chen H, Chang X, Weng T, *et al.* A study of microemulsion systems for transdermal delivery of triptolide. *J Control Release* 2004; 98(3): 427-36.
[<http://dx.doi.org/10.1016/j.jconrel.2004.06.001>] [PMID: 15312998]
- [115] Aggarwal BB, Van Kuiken MEV, Iyer LH, Harikumar KB, Sung B. Molecular targets of nutraceuticals derived from dietary spices: potential role in suppression of inflammation and tumorigenesis. *Exp Biol Med (Maywood)* 2009; 234(8): 825-49.
[<http://dx.doi.org/10.3181/0902-MR-78>] [PMID: 19491364]
- [116] McClements DJ, Li F, Xiao H. The nutraceutical bioavailability classification scheme: classifying nutraceuticals according to factors limiting their oral bioavailability. *Annu Rev Food Sci Technol* 2015; 6: 299-327.
[<http://dx.doi.org/10.1146/annurev-food-032814-014043>] [PMID: 25705933]
- [117] Acosta E. Bioavailability of nanoparticles in nutrient and nutraceutical delivery. *Curr Opin Colloid Interface Sci* 2009; 14(1): 3-15.
[<http://dx.doi.org/10.1016/j.cocis.2008.01.002>]
- [118] Gopi S, Amalraj A, Haponiuk JT, Thomas S. Introduction of nanotechnology in herbal drugs and nutraceutical: A Review. *J Nanomedicine Biotherapeutic Discov* 2016; 6(2): 1-8.
[<http://dx.doi.org/10.4172/2155-983X.1000143>]

Pharmaceutical Nanosciences and their Application in the Delivery of Various Phytoconstituents

ORIGINALITY REPORT

5%

SIMILARITY INDEX

4%

INTERNET SOURCES

2%

PUBLICATIONS

0%

STUDENT PAPERS

PRIMARY SOURCES

| | | |
|---|--|-----|
| 1 | www.longdom.org Internet Source | 1% |
| 2 | Fan Cao, Ming-Han Cheng, Li-Qin Hu, Hui-Hui Shen, Jin-Hui Tao, Xiao-Mei Li, Hai-Feng Pan, Jian Gao. "Natural products action on pathogenic cues in autoimmunity: Efficacy in systemic lupus erythematosus and rheumatoid arthritis as compared to classical treatments", Pharmacological Research, 2020 Publication | 1% |
| 3 | worldwidescience.org Internet Source | <1% |
| 4 | www.omicsonline.org Internet Source | <1% |
| 5 | bjp.sagepub.unboundmedicine.com Internet Source | <1% |
| 6 | Chen, Xiuping, Jiaolin Bao, Jiajie Guo, Qian Ding, Jinjian Lu, Mingqing Huang, and Yitao Wang. "Biological activities and potential | <1% |

molecular targets of cucurbitacins : a focus on cancer", Anti-Cancer Drugs, 2012.

Publication

| | | |
|----|---|------|
| 7 | www.canada.ca Internet Source | <1 % |
| 8 | www.unboundmedicine.com Internet Source | <1 % |
| 9 | Wei-Sheng Chung, Cheng-Li Lin. "Sleep disorders associated with risk of rheumatoid arthritis", Sleep and Breathing, 2018 Publication | <1 % |
| 10 | Prince Allawadhi, Vishakha Singh, Kannan Govindaraj, Isha Khurana et al. "Biomedical applications of polysaccharide nanoparticles for chronic inflammatory disorders: Focus on rheumatoid arthritis, diabetes and organ fibrosis", Carbohydrate Polymers, 2021 Publication | <1 % |
| 11 | bmccomplementalternmed.biomedcentral.com Internet Source | <1 % |
| 12 | ijbch.kaznu.kz Internet Source | <1 % |
| 13 | coek.info Internet Source | <1 % |
| 14 | Ana Henriques Mota, Alexandra Sousa, Mariana Figueira, Mariana Amaral et al. | <1 % |

"Natural-based consumer health nanoproducts: medicines, cosmetics, and food supplements", Elsevier BV, 2020

Publication

15

Orlando David Henrique dos Santos, Pedro Alves da Rocha-Filho. "Influence of Surfactant on the Thermal Behavior of Marigold Oil Emulsions with Liquid Crystal Phases", Drug Development and Industrial Pharmacy, 2008

Publication

<1 %

16

pjms.com.pk

Internet Source

<1 %

17

Uche O Arunsi, Ogbuka E Chioma, Paschal E Etusim, Solomon E Owumi. "Indigenous Nigeria medicinal herbal remedies: A potential source for therapeutic against rheumatoid arthritis", Experimental Biology and Medicine, 2022

Publication

<1 %

Exclude quotes Off

Exclude matches Off

Exclude bibliography On

Pharmaceutical Nanosciences and their Application in the Delivery of Various Phytoconstituents

GRADEMARK REPORT

FINAL GRADE

/0

GENERAL COMMENTS

Instructor

PAGE 1

PAGE 2

PAGE 3

PAGE 4

PAGE 5

PAGE 6

PAGE 7

PAGE 8

PAGE 9

PAGE 10

PAGE 11

PAGE 12

PAGE 13

PAGE 14

PAGE 15

PAGE 16

PAGE 17

PAGE 18

PAGE 19

PAGE 20

PAGE 21

PAGE 22

PAGE 23

PAGE 24

PAGE 25

PAGE 26

PAGE 27

PAGE 28

PAGE 29

PAGE 30

PAGE 31

PAGE 32
